Nurix Therapeutics, Inc.
US ˙ NasdaqGM ˙ US67080M1036

SecurityNRIX / Nurix Therapeutics, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership477,410 shares
Latest Disclosed Value $ 7,399,855
Citigroup Inc reports 179.02% increase in ownership of NRIX / Nurix Therapeutics, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 477,410 shares of Nurix Therapeutics, Inc. (US:NRIX) valued at $7,399,855 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 171,102 shares of Nurix Therapeutics, Inc.. This represents a change in shares of 179.02% during the quarter. The current value of the position is $7,294,825 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F NURIX THERAPEUTICS COM 67080M103 477,410 306,308 179.02 7,400 128.01 0.0016
2026-02-13 2025-12-31 13F NURIX THERAPEUTICS COM 67080M103 171,102 163,735 2,222.55 3,246 4,672.06 0.0014
2025-11-10 2025-09-30 13F NURIX THERAPEUTICS COM 67080M103 7,367 -36,360 -83.15 68 -86.35 0.0000
2025-08-11 2025-06-30 13F NURIX THERAPEUTICS COM 67080M103 43,727 -96,739 -68.87 498 -70.14 0.0002
2025-05-12 2025-03-31 13F NURIX THERAPEUTICS COM 67080M103 140,466 33,116 30.85 1,669 -17.51 0.0009
2025-02-12 2024-12-31 13F NURIX THERAPEUTICS COM 67080M103 107,350 57,757 116.46 2,022 81.51 0.0012
2024-11-12 2024-09-30 13F NURIX THERAPEUTICS COM 67080M103 49,593 22,171 80.85 1,114 94.76 0.0006
2024-08-12 2024-06-30 13F NURIX THERAPEUTICS COM 67080M103 27,422 -157,358 -85.16 572 -78.94 0.0004
2024-05-10 2024-03-31 13F NURIX THERAPEUTICS COM 67080M103 184,780 169,635 1,120.07 2,716 1,641.03 0.0018
2024-02-09 2023-12-31 13F NURIX THERAPEUTICS COM 67080M103 15,145 -27,055 -64.11 156 -52.87 0.0001
2023-12-06 2023-09-30 13F/A-1 NURIX THERAPEUTICS COM 67080M103 42,200 -4,760 -10.14 332 -29.42 0.0002
2023-11-09 2023-09-30 13F NURIX THERAPEUTICS COM 67080M103 42,200 -4,760 332 0.0001
2023-08-10 2023-06-30 13F NURIX THERAPEUTICS COM 67080M103 46,960 -66,144 -58.48 469 -53.29 0.0003
2023-05-11 2023-03-31 13F NURIX THERAPEUTICS COM 67080M103 113,104 39,508 53.68 1,004 24.26 0.0007
2023-02-09 2022-12-31 13F NURIX THERAPEUTICS COM 67080M103 73,596 -46,922 -38.93 808 -48.54 0.0006
2022-11-10 2022-09-30 13F NURIX THERAPEUTICS COM 67080M103 120,518 45,253 60.12 1,570 64.57 0.0011
2022-08-10 2022-06-30 13F NURIX THERAPEUTICS COM 67080M103 75,265 50,085 198.91 954 170.25 0.0007
2022-05-12 2022-03-31 13F NURIX THERAPEUTICS COM 67080M103 25,180 -51,431 -67.13 353 -84.08 0.0002
2022-02-10 2021-12-31 13F NURIX THERAPEUTICS COM 67080M103 76,611 -44,041 -36.50 2,218 -38.64 0.0012
2021-11-10 2021-09-30 13F NURIX THERAPEUTICS COM 67080M103 120,652 -1,859 -1.52 3,615 11.23 0.0021
2021-08-10 2021-06-30 13F NURIX THERAPEUTICS COM 67080M103 122,511 37,755 44.55 3,250 23.34 0.0020
2021-05-13 2021-03-31 13F NURIX THERAPEUTICS COM 67080M103 84,756 81,242 2,311.95 2,635 2,171.55 0.0017
2021-02-11 2020-12-31 13F NURIX THERAPEUTICS COM 67080M103 3,514 2,981 559.29 116 510.53 0.0001
2020-11-12 2020-09-30 13F NURIX THERAPEUTICS COM 67080M103 533 533 19 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.